SUNY Upstate Researchers Secured Lung Therapy Grant

The research team is developing a targeted treatment for acute respiratory distress syndrome.

Updated on Sept. 26, 2026 in Asthma

A stainless steel lab bench with glass laboratory equipment under cool, clinical lighting, conveying a medical research environment. — SUNY Upstate Medical University researchers secured a new grant to develop a novel targeted therapy for acute respiratory distress syndrome. AI Illustration. Upload story photo >

SUNY Upstate Medical University researchers have received a new grant to develop a novel therapy for acute respiratory distress syndrome. This project aims to address the dangerous fluid accumulation in air sacs that characterizes the condition.

Why it matters

Acute respiratory distress syndrome poses significant risks to patients by inhibiting oxygen exchange in the lungs. Developing localized drug delivery methods could improve outcomes for those suffering from severe respiratory failure.

The project focuses on delivering drugs directly to the lungs of patients to mitigate fluid buildup. Researchers are currently evaluating the efficacy of this delivery method against traditional treatment baselines.

The players

SUNY Upstate Medical University

This institution is a major academic medical center located in Syracuse that focuses on biomedical research and clinical care.

Dr. Stephen Thomas

He is a researcher associated with SUNY Upstate Medical University who discussed the recent lung therapy grant.

The details

The project aims to treat fluid buildup in air sacs associated with acute respiratory distress syndrome. Researchers are working to refine a method for delivering therapeutic drugs directly to the lungs to improve patient stability.

September 26, 2026: Dr. Stephen Thomas discussed the new research grant.

Deeper Dive

This project aligns with the goals established by the National Institutes of Health ARDS research initiatives. The study represents a localized approach that departs from broader systemic treatments currently in practice.

The development of localized lung therapies could eventually offer patients more effective treatment options with fewer systemic side effects. Residents in the area should look for future clinical trial opportunities as the project progresses.

The takeaway

Advancements in targeted pulmonary drug delivery could significantly change how clinicians manage acute respiratory distress. Researchers suggest that focusing on direct lung administration may reduce the recovery time for patients suffering from respiratory complications.